Answers are grounded in this paper and cite their sources.
Background: An understanding of real-world nirmatrelvir/ritonavir (NMV-r; Paxlovid™) use in Canada is needed to inform strategies for therapy access and use. Objective: To describe the characteristics of adults who received NMV-r in Alberta, Canada. Methods: Population-level administrative data was used to describe adults (18 years and older) who received an outpatient dispensation of NMV-r between January 2022 and March 2023 in Alberta. Omicron variants predominated during this period. Results: Mean age of the cohort (n=11,793) was 65 years (standard deviation=18), 60.4% were female and 83.9% had one or more health condition associated with a risk for the development of severe COVID-19 outcomes. In comparison to the general Alberta population, a larger proportion of those that received NMV-r resided in urban areas (Alberta: 82.3%; NMV-r: 89.8%) and were more socioeconomically well-off (Material Deprivation Index quintile 1-Alberta: 20.0%; NMV-r: 25.8%). A total of 81.6% received three or more COVID-19 vaccine doses and 7.0% received one or no dose. The majority of dispensed NMV-r prescriptions were from physicians (83.6%), with 13.5% from pharmacists and 2.9% from other healthcare providers. Conclusion: In Alberta, adults who received outpatient NMV-r displayed characteristics associated with risk for progression to severe COVID-19 outcomes (related to age and health conditions) and healthcare-seeking behaviour (older age, female sex, presence of health conditions, higher socioeconomic status and highly vaccinated). Provision by urban/rural and socioeconomic status were noted. Findings can be used to inform strategies for overcoming barriers and ensuring equitable access to COVID-19 therapy for all who are most likely to benefit.
No takes yet. Share an insight, caveat, or question.
Vu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: